Alnylam, Arrowhead partner to pursue RNAi therapies for hepatitis B
This article was originally published in Scrip
Executive Summary
Under a new alliance, Alnylam Pharmaceuticals has granted a license to its RNAi technology to Arrowhead Research in a pact aimed at discovering, developing and commercializing a therapeutic targeting hepatitis B virus (HBV).